US Post-Market Study of the Surfacer System for Central Venous Access

This study is looking at the Surfacer® Inside-Out® Access Catheter System. This device helps doctors get central venous access (a way to put a catheter, or thin tube, into a large vein) in people who have blockages in their upper body veins or other issues that make it hard to get access in the usual way. The study wants to see how well the device works to get central venous access and if there are any problems within 24 hours. You might be able to join if you are 18 or older, need central venous access, and have conditions that prevent conventional access. The study is currently unclear on its recruitment status and plans to enroll at least 30 participants.

Study design
This is an observational study, meaning researchers will watch how the Surfacer System is used in real-world settings. It will enroll at least 30 participants across multiple sites.
What's involved
You would be treated with the Surfacer System according to its approved use. Your data would be collected, and you would sign an informed consent form.
Compensation
Not stated in the trial record.
Follow-up
Researchers will check for operational success and adverse events within 24 hours after the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05050799

US Post-Market Surveillance Study of the Surfacer System

Recruiting
Not specifiedAges 18+Observational
Merit Medical Systems, Inc.
~30 participants
Updated 2026-06-01 on ClinicalTrials.gov
What's tested:Central Venous Access

At a glance

Recruiting sites
7 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Central Venous Access operational
Measured over 24 hours
+1 more outcome measured
Venous Disease
9 sites across 7 states
Texas3
Arizona1
Florida1
Georgia1
Ohio1
Utah1
Virginia1

Opens a ready-to-send draft in your own email app — review before sending.

  • Central Venous Access operational24 hours

    safe insertion of the device to facilitate central venous access

  • Incidence of adverse events through 24 hours24 hours

    no procedural adverse events or peri procedural adverse events